Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Horien Biochemical Technology Co's Revenue for the
three
months ended in Mar. 2026 was NT$23.65 Mil. Horien Biochemical Technology Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$10.05 Mil.
Hence, Horien Biochemical Technology Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.35.
Horien Biochemical Technology Co (ROCO:7814) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Horien Biochemical Technology Co Receivables Turnover Related Terms
Horien Biochemical Technology Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horien Biochemical Technology Co Receivables Turnover Chart
ROCO:7814 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Horien Biochemical Technology Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Horien Biochemical Technology Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Horien Biochemical Technology Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Horien Biochemical Technology Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Horien Biochemical Technology Co (ROCO:7814) has a Receivables Turnover of 2.35 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Horien Biochemical Technology Co and its competitors. According to the industry distribution chart, Horien Biochemical Technology Co ranks #216 out of 845 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Horien Biochemical Technology Co's Receivables Turnover too high?
Horien Biochemical Technology Co's current Receivables Turnover is 2.35. The Biotechnology industry median Receivables Turnover is 5.22. Horien Biochemical Technology Co's value of 2.35 is 55% below this industry median. Based on the distribution chart, Horien Biochemical Technology Co ranks #216 out of 845 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Horien Biochemical Technology Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Horien Biochemical Technology Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Horien Biochemical Technology Co ranks #216 out of 845 companies for Receivables Turnover. This puts Horien Biochemical Technology Co in the upper half of its industry. The industry median Receivables Turnover is 5.22. Horien Biochemical Technology Co's value of 2.35 is 55% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.22, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Horien Biochemical Technology Co's current Receivables Turnover of 2.35 is 55% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Horien Biochemical Technology Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Horien Biochemical Technology Co's current Receivables Turnover is 2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Horien Biochemical Technology Co stock overvalued right now?
Horien Biochemical Technology Co (ROCO:7814) has a current Receivables Turnover of 2.35. The current Receivables Turnover is 2.35 and 55% below the Biotechnology industry median of 5.22. Horien Biochemical Technology Co's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Horien Biochemical Technology Co (ROCO:7814), the current Receivables Turnover is 2.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Horien Biochemical Technology Co Ltd is engaged in the research and development of cosmetic raw materials and medical devices and facilities. The products of the company include Gen-Nusis, skin repairment ingredients, PeptioMax, the latest cosmetic raw material, Lifkin, and other substitutes used in dentistry and general surgery.
19GF Score
Get the complete analysis for ROCO:7814
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7814 has been successfully added to your 
